As the introduction of new member states to the European Union edges closer, the debate in Brussels regarding healthcare for the enlarged Union becomes more heated. Health standards in new member states are predicted to increase, but the main worry for the usual protagonists is how will the European pharmaceutical industry fare?

This article is currently available in printed form only.


 To ensure access to all articles from every issue of 